BioMarin Pharmaceutical (BMRN) – Research Analysts’ Recent Ratings Changes

A number of research firms have changed their ratings and price targets for BioMarin Pharmaceutical (NASDAQ: BMRN):

• 9/17/2024 – BioMarin Pharmaceutical had its price target lowered by analysts at Scotiabank from $95.00 to $78.00. They now have a “sector perform” rating on the stock.
• 9/17/2024 – BioMarin Pharmaceutical had its price target lowered by analysts at Royal Bank of Canada from $100.00 to $85.00. They now have a “sector perform” rating on the stock.
• 9/17/2024 – BioMarin Pharmaceutical had its price target lowered by analysts at Wells Fargo & Company from $115.00 to $90.00. They now have an “overweight” rating on the stock.
• 9/17/2024 – BioMarin Pharmaceutical had its price target lowered by analysts at Sanford C. Bernstein from $116.00 to $90.00. They now have an “outperform” rating on the stock.
• 9/17/2024 – BioMarin Pharmaceutical had its price target lowered by analysts at Truist Financial Co. from $118.00 to $90.00. They now have a “buy” rating on the stock.
• 9/17/2024 – BioMarin Pharmaceutical had its price target lowered by analysts at Stifel Nicolaus from $115.00 to $87.00. They now have a “buy” rating on the stock.
• 9/17/2024 – BioMarin Pharmaceutical had its price target lowered by analysts at Bank of America Co. from $130.00 to $115.00. They now have a “buy” rating on the stock.
• 9/13/2024 – BioMarin Pharmaceutical had its “hold” rating reaffirmed by analysts at Canaccord Genuity Group Inc.. They now have a $93.00 price target on the stock.
• 9/9/2024 – BioMarin Pharmaceutical had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $110.00 price target on the stock.
• 9/5/2024 – BioMarin Pharmaceutical had its “sector perform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $100.00 price target on the stock.
• 9/5/2024 – BioMarin Pharmaceutical had its price target raised by analysts at Scotiabank from $86.00 to $95.00. They now have a “sector perform” rating on the stock.
• 9/5/2024 – BioMarin Pharmaceutical had its price target raised by analysts at JPMorgan Chase & Co. from $111.00 to $120.00. They now have an “overweight” rating on the stock.
• 9/5/2024 – BioMarin Pharmaceutical had its price target raised by analysts at Piper Sandler from $107.00 to $122.00. They now have an “overweight” rating on the stock.
• 9/5/2024 – BioMarin Pharmaceutical had its price target lowered by analysts at Truist Financial Co. from $140.00 to $118.00. They now have a “buy” rating on the stock.
• 8/30/2024 – BioMarin Pharmaceutical was upgraded by analysts at William Blair to a “strong-buy” rating.
• 8/27/2024 – BioMarin Pharmaceutical had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $107.00 price target on the stock.
• 8/21/2024 – BioMarin Pharmaceutical had its price target raised by analysts at Stifel Nicolaus from $112.00 to $115.00. They now have a “buy” rating on the stock.
• 8/20/2024 – BioMarin Pharmaceutical was upgraded by analysts at Sanford C. Bernstein from a “market perform” rating to an “outperform” rating. They now have a $110.00 price target on the stock, up previously from $94.00.
• 8/8/2024 – BioMarin Pharmaceutical was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
• 8/6/2024 – BioMarin Pharmaceutical had its price target raised by analysts at Scotiabank from $85.00 to $86.00. They now have a “sector perform” rating on the stock.
• 8/6/2024 – BioMarin Pharmaceutical had its “sector perform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $100.00 price target on the stock.
• 8/6/2024 – BioMarin Pharmaceutical had its price target lowered by analysts at Barclays PLC from $111.00 to $110.00. They now have an “overweight” rating on the stock.
• 8/6/2024 – BioMarin Pharmaceutical had its price target raised by analysts at Evercore ISI from $113.00 to $115.00. They now have an “outperform” rating on the stock.
• 8/6/2024 – BioMarin Pharmaceutical had its price target lowered by analysts at TD Cowen from $125.00 to $120.00. They now have a “buy” rating on the stock.
• 8/6/2024 – BioMarin Pharmaceutical had its price target raised by analysts at Stifel Nicolaus from $108.00 to $112.00. They now have a “buy” rating on the stock.
• 8/5/2024 – BioMarin Pharmaceutical had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $110.00 price target on the stock.

BioMarin Pharmaceutical Trading Down 0.6 %

BMRN opened at $69.66 on Thursday. The stock has a market capitalization of $13.23 billion, a PE ratio of 65.10, a P/E/G ratio of 0.80 and a beta of 0.32. BioMarin Pharmaceutical Inc. has a one year low of $67.75 and a one year high of $99.56. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.95 and a current ratio of 3.05. The business’s 50 day moving average price is $83.20 and its 200 day moving average price is $83.40.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings results on Monday, August 5th. The biotechnology company reported $0.77 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.39. The business had revenue of $712.03 million during the quarter, compared to analysts’ expectations of $660.51 million. BioMarin Pharmaceutical had a net margin of 9.91% and a return on equity of 6.91%. As a group, equities research analysts expect that BioMarin Pharmaceutical Inc. will post 2.39 EPS for the current year.

Hedge Funds Weigh In On BioMarin Pharmaceutical

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Innealta Capital LLC purchased a new position in BioMarin Pharmaceutical in the 2nd quarter valued at approximately $25,000. BOKF NA purchased a new position in BioMarin Pharmaceutical in the second quarter valued at $31,000. Quent Capital LLC grew its stake in BioMarin Pharmaceutical by 58.9% during the 2nd quarter. Quent Capital LLC now owns 391 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 145 shares in the last quarter. Jones Financial Companies Lllp purchased a new stake in BioMarin Pharmaceutical during the 4th quarter worth about $43,000. Finally, Itau Unibanco Holding S.A. acquired a new stake in BioMarin Pharmaceutical in the 2nd quarter valued at about $47,000. 98.71% of the stock is currently owned by hedge funds and other institutional investors.

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.